Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

@article{Liu2016RandomizedPI,
  title={Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.},
  author={Joyce Liu and Isabelle Ray-Coquard and Fr{\'e}d{\'e}ric Selle and A. M. Soto Poveda and David Cibula and Hal W. Hirte and Felix Hilpert and Francesco Raspagliesi and Laurence Gladieff and Philipp Harter and Salvatore Siena and Josep Mar{\'i}a Del Campo and Isabelle Tabah-Fisch and Joseph Pearlberg and Victor M. Moyo and Kaveh Riahi and Rachel Nering and William Kubasek and Bambang S. Adiwijaya and Akos Gabor Czibere and Robert Wendel Naumann and Robert L Coleman and Ignace Vergote and Gavin MacBeath and {\'E}ric Pujade-Lauraine},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 36},
  pages={
          4345-4353
        }
}
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or -refractory ovarian cancer. A key… CONTINUE READING
BETA
1
Twitter Mention

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Development of Effective Therapeutics Targeting HER3 for Cancer Treatment

  • Biological procedures online
  • 2019
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED